GIP and type 2 diabetes mellitus: Tirzepatide is an innovative dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved for type II diabetes therapy, improving glycemic control to a greater extent than selective GLP-1 receptor agonists [16].